Scarica l'app Stockscreener
17.34
4.46%
-0.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$18.15
Aprire:
$18.12
Volume 24 ore:
273.99K
Relative Volume:
0.88
Capitalizzazione di mercato:
$964.44M
Reddito:
$7.48M
Utile/perdita netta:
$-60.50M
Rapporto P/E:
-15.41
EPS:
-1.1251
Flusso di cassa netto:
$-52.28M
1 W Prestazione:
-6.37%
1M Prestazione:
-25.58%
6M Prestazione:
+2.73%
1 anno Prestazione:
+46,513%
Intervallo 1D:
$17.31
$18.19
Intervallo di 1 settimana:
$16.99
$18.75
Portata 52W:
$0.033
$34.19
Aktis Oncology Inc Stock (AKTS) Company Profile
Nome
Aktis Oncology Inc
Settore
Industria
Telefono
978-237-4380
Indirizzo
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
17.34 | 964.44M | 7.48M | -60.50M | -52.28M | -1.1251 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-09 | Iniziato | Oppenheimer | Outperform |
| 2026-08-19 | Iniziato | BMO Capital Markets | Outperform |
| 2026-08-19 | Iniziato | Wedbush | Outperform |
| 2026-06-16 | Iniziato | Raymond James | Strong Buy |
| 2026-04-29 | Iniziato | William Blair | Outperform |
| 2026-03-09 | Iniziato | H.C. Wainwright | Buy |
| 2026-02-03 | Iniziato | BofA Securities | Buy |
| 2026-02-03 | Iniziato | JP Morgan | Overweight |
| 2026-02-03 | Iniziato | Leerink Partners | Outperform |
| 2026-02-03 | Iniziato | TD Cowen | Buy |
| 2024-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | Iniziato | B. Riley Securities | Buy |
| 2021-02-02 | Reiterato | Craig Hallum | Buy |
| 2021-01-15 | Reiterato | Craig Hallum | Buy |
| 2019-09-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | Reiterato | Craig Hallum | Buy |
| 2019-02-05 | Reiterato | Craig Hallum | Buy |
| 2019-02-05 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | Iniziato | Craig Hallum | Buy |
| 2018-11-30 | Iniziato | Lake Street | Buy |
| 2018-06-22 | Iniziato | Loop Capital | Buy |
| 2018-02-09 | Iniziato | Drexel Hamilton | Buy |
Mostra tutto
Aktis Oncology Inc Borsa (AKTS) Ultime notizie
Form 144 AKTIS ONCOLOGY INC For: 26 September By Investing.com - Investing.com Nigeria
Aktis Oncology (AKTS) medical chief exercises options and sells shares under a trading plan. - Stock Titan
After selling 50,000 shares in July, an Aktis Oncology (AKTS) officer plans another sale. - Stock Titan
Aktis Oncology (AKTS) Gains 2.64% as Shares Push Back Toward $22MFI Oversold - dars.gov.et
AKTS Initiated Coverage by Oppenheimer -- Rating Set to Outperform - GuruFocus
Two New York investor events will include Aktis Oncology's CEO - Stock Titan
Oppenheimer initiates Aktis Oncology stock rating at Outperform - Investing.com
Oppenheimer initiates Aktis Oncology stock rating at Outperform By Investing.com - Investing.com Canada
Aktis Oncology (NASDAQ:AKTS) Trading Down 7.3%Should You Sell? - MarketBeat
Wellington Management Group LLP Takes $63.37 Million Position in Aktis Oncology $AKTS - MarketBeat
Aktis Oncology $AKTS Shares Purchased by BlackRock Inc. - MarketBeat
AKTS Q2 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Net LossQuarterly Profit Report - vinanet.vn
Jupiter Topco LLC Invests $42.36 Million in Aktis Oncology $AKTS - MarketBeat
Great Lakes Advisors LLC Takes $1.41 Million Position in Aktis Oncology $AKTS - MarketBeat
Blue Owl Capital Holdings LP Sells 91,129 Shares of Aktis Oncology $AKTS - MarketBeat
Aktis (AKTS) Earnings Snapshot: EPS Comes in Below Forecast in the Latest Session; Closing Reaction: The Share Price Sheds 4.08%Margin Guidance - vinanet.vn
Aktis (AKTS) Earnings Snapshot: EPS Comes in Below Forecast in the Latest Session; Closing Reaction: The Share Price Sheds 4.08%Low Growth Earnings - careplusvn.com
AKTIS ONCOLOGY INC : WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $35 - Bitget
Wedbush initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com South Africa
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - Yahoo Finance
Wedbush initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com Canada
Wedbush initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com UK
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target - marketscreener.com
AKTS Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
BMO initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com Canada
Aktis Oncology (AKTS) Slips to $24.72 as Shares Trade Within Established RangeSynthetic Long - vinanet.vn
Aktis Oncology (AKTS) Slips to $24.72 as Shares Trade Within Established RangeLow Vol Factor - siam.in
AKTS Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Oncology Pipeline InvestmentLow Growth Earnings - vinanet.vn
Aktis Oncology, Inc.: Target Price Consensus and Analysts Recommendations | AKTS | US01021M1045 - marketscreener.com
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
AKTS SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations - marketbeat.com
Aktis Oncology Q2 EPS misses estimate, sales beat consensus - scanx.trade
Aktis: Q2 Earnings Snapshot - KING5.com
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 - The Manila Times
Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029 - Stock Titan
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 - GlobeNewswire
Aktis Oncology (AKTS) Gains 2.94% as Shares Approach Key Resistance at $25.34Dividend ETF - dars.gov.et
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aktis Oncology (AKTS) Slips 1.5% as Shares Hover Above Key Support at $20.64Stop Run - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share Highlights Pre-Revenue ChallengesAnalyst Drop Coverage - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share, Yet Shares Climb 2.72%Revenue Warning Signal - vinanet.vn
Insider Selling: Aktis Oncology (NASDAQ:AKTS) Director Sells 4,856 Shares of Stock - MarketBeat
AKTS|Akoustis Technologies Ord Shs|Price:24.170|Chg%:+0.280 - TradingKey
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st
AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33 - Bitget
Aktis Oncology Inc Azioni (AKTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aktis Oncology Inc Azioni (AKTS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Czibere Akos | Chief Medical Officer |
Sep 23 '26 |
Sale |
20.69 |
12,500 |
258,621 |
0 |
| Akos Czibere | Officer |
Sep 23 '26 |
Proposed Sale |
22.11 |
25,000 |
552,750 |
0 |
| Herrmann Ken | Director |
Jul 20 '26 |
Option Exercise |
0.59 |
4,856 |
2,859 |
4,856 |
| KEN HERRMANN | Director |
Jul 20 '26 |
Proposed Sale |
24.56 |
4,856 |
119,275 |
0 |
| Herrmann Ken | Director |
Jul 20 '26 |
Sale |
24.56 |
4,856 |
119,274 |
0 |
| KEN HERRMANN | Director |
Jul 17 '26 |
Proposed Sale |
25.21 |
3,065 |
77,259 |
0 |
| Herrmann Ken | Director |
Jul 17 '26 |
Sale |
25.21 |
3,065 |
77,259 |
0 |
| Herrmann Ken | Director |
Jul 17 '26 |
Option Exercise |
0.08 |
3,065 |
245 |
3,065 |
| Czibere Akos | Chief Medical Officer |
Jul 08 '26 |
Option Exercise |
4.95 |
50,000 |
247,500 |
50,000 |
| Ron-Bigger Shulamit | Chief Operating Officer |
Jul 08 '26 |
Option Exercise |
3.66 |
50,000 |
183,000 |
50,000 |
3.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):